Skip to main content

Articles

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD

Stanton R. Mehr

Practice Management

Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends

Christopher B. Atzinger, MS, PhD candidate; Jeff J. Guo, BPharm, PhD

Stakeholder Perspective

Rheumatoid Arthritis, Biologic Drugs, and Associated Cost

Byron C. Scott, MD, MBA

Practice Management

Top 10 Healthcare Market Trends in 2017

John Santilli, MBA, and F. Randy Vogenberg, RPh, PhD

Practice Management

Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States

Joseph Lee, PhD; Ryan Pelkey, MS; Julieanna Gubitosa, BS; Michael F. Henrick, MBA; Michael L. Ganz, MS, PhD

Stakeholder Perspective

Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers

Gary Branning, MBA

Practice Management

BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma

Leukemia, Oncology

American Society of Hematology 2016: Leukemia Highlights

Practice Management

Increased Utilization of Biosimilars in Oncology Could Save Payers Millions

Practice Management

Value Frameworks Unreliable in Assessing Novel Hematologic Therapies

Practice Management

Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma

Practice Management

ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia

Page 95 of 244
Results 941 - 950 of 2436